Introduction
============

Rheumatoid arthritis (RA) is an inflammatory joint disease which may cause joint damage, disability and fatigue ([@ref-41]). RA patients experience fatigue as unpredictable, overwhelming and different from normal tiredness ([@ref-17]). Fatigue is caused by numerous factors. This might due to immunological disorders, hormonal imbalances, decrease in oxygenation, and exogenous processes induced by drugs ([@ref-15]). A conceptual model for fatigue suggests inter-relationships between and within the RA disease process, personal issues, feelings, thoughts and behaviors ([@ref-24]). Fatigue in RA is under-recognized and undertreated ([@ref-25]). Furthermore, it is one of the most burdensome symptoms from the patient perspective ([@ref-30]; [@ref-45]). Over the last decades biologic agents have caused a paradigm shift in the treatment of RA, and biologics are effective in reducing disease activity, inflammation, pain and joint damage in RA ([@ref-41]). This reduction of disease-related components may affect the level of RA fatigue, and previous research has shown that both anti-tumor necrosis factor (anti-TNF) and non-anti-TNF biologics produce similar improvements in fatigue ([@ref-4]). However, patient-reported consequences of disease activity may differ from the assessments made by health professionals ([@ref-42]).

Background
==========

Recommendations endorsed by the European League Against Rheumatism and the American College of Rheumatology encourage all clinical trials to report fatigue ([@ref-2]; [@ref-30]). Fatigue is a patient-reported measure and can incorporate one single item or multiple items. Furthermore, the scales can have a unidimensional or multidimensional structure. The Fatigue Severity Scale (FSS) is a disease-specific questionnaire intended to assess fatigue in multiple sclerosis and systemic lupus patients, but it is also used in RA studies ([@ref-12]; [@ref-20]; [@ref-27]). The FSS is better at detecting changes than generic questionnaires ([@ref-26]). As fatigue in RA patients is measured by various patient-reported outcome measures ([@ref-26]; [@ref-39]), and as results from these measures are difficult to compare, the review below will mainly refer to research based on the FSS.

Effect of biologic therapy on fatigue
-------------------------------------

Only a few previous studies have examined the effect of biologic therapy on fatigue measured with a disease-specific scale. In a double-blinded study, patients with Primary Sjögren's syndrome received biologic therapy or placebo, and fatigue was measured using both the FSS and Visual Analogue Scale (VAS). After four weeks of treatment there was no significant reduction in fatigue in these patients ([@ref-36]). On the other hand, another study has evaluated the effect of biologic therapy on work ability, fatigue and functional disability in RA patients after six months. In this study, fatigue was measured using the FSS and VAS, and the results demonstrated that biologics had a beneficial effect on fatigue in patients with RA ([@ref-27]).

Predictors for changes in fatigue
---------------------------------

As stated by Ahmed and colleagues, patient-reported outcomes are important as they represent information from the patient perspective that has not been interpreted by health personnel ([@ref-1]) and such measures might provide additional and different information that is relevant for both RA patients and physicians ([@ref-21]).

Previous research has identified both patient-reported factors and more objective measures evaluated by health personnel as predictors for fatigue. In a review containing both cross-sectional and longitudinal studies, as well as several measures of fatigue, the results showed a correlation between fatigue and patient-reported pain, physical function and depression ([@ref-35]). In a systematic review of cross-sectional, observational and cohort studies examining psychological factors as predictors for fatigue, there was a consistent correlation between patient-reported mood and fatigue, with low mood being associated with increased fatigue ([@ref-34]). The most common health personnel-reported measure of disease activity in patients with RA is the Disease Activity Scale 28 (DAS28) ([@ref-48]). To our knowledge, no previous studies including both patient-reported and health personnel-reported measures have measured fatigue using the FSS. In a previous study of both patient-reported and health personnel-reported outcomes, results showed that disease activity, pain, sleep disturbance, and mental health were related to fatigue ([@ref-44]). A review of correlations between different disease activity measures, pain and fatigue showed that pain was the strongest factor associated with fatigue ([@ref-33]). In these studies gender has not been considered as a possible predictor for change in fatigue. In a study of patients in remission or with low disease activity, pain was a significant predictor of fatigue ([@ref-37]).

Regarding sociodemographic data, gender differences have been observed in previous research. Female patients reported significantly higher fatigue measured by the FSS compared with healthy controls ([@ref-9]), and female participants reported more persistent fatigue after four years than men did ([@ref-14]). In a study, [@ref-44] found that women reported more fatigue measured by the VAS than men. Furthermore, one study found a difference between the patient and physician assessment of global disease activity, and this difference was more pronounced in women than in men ([@ref-32]).

The aims of the present study were:

1.  To examine changes in patient-reported fatigue in RA patients who commence biologic treatment;

2.  To identify possible predictors (sociodemographic as well as patient-reported and health personnel-reported variables) for changes in fatigue.

Methods
=======

Design
------

The study was carried out at a rheumatology specialist department in Western Norway. It was a longitudinal study comparing fatigue levels over 12 months. Patients were assessed at baseline (T0) and after 3 (T1), 6 (T2) and 12 months (T3). The study was part of an observational study to explore ultrasonographic differences in total synovitis between seropositive and seronegative rheumatoid arthritis patients. The patients consented to participate in both studies at the same time.

Inclusion criteria were as follows and the same as in the main study: (1) male or non-pregnant, non-nursing female; (2) age between 18 and 75 years; (3) patient classified as having RA according to the 2010 American College of Rheumatology/ European League Against Rheumatism criteria ([@ref-3]); (4) treating rheumatologist and patient have decided that biologic treatment is needed; (5) patient has had no prior biologic treatment; and (6) patient is able and willing to give written informed consent and comply with the requirements of the study protocol. Exclusion criteria: (1) abnormal renal function (serum creatinine \>142 µmol/L in female and \>168 µmol/L in male, or GFR \<40 mL/min/1.73 m^2^; (2) abnormal liver function (ASAT/ALAT \> 3 times normal), active or recent hepatitis, cirrhosis; (3) major co-morbidities like severe malignancies, severe diabetic mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (New York Heart Association Functional Class 3--4) and/or severe respiratory disease; (4) leukopenia and/or thrombocytopenia; (5) inadequate birth control, pregnancy, and/or breastfeeding; (6) indications of active tuberculosis; and (7) psychiatric or mental disorders, alcohol abuse or other abuse of substances, language barriers or other factors which make adherence to the study protocol impossible.

Data collection
---------------

During the period from October 2011 to December 2014, all eligible patients were invited to enter the study. A physical examination, including checking for co-morbidities and joint counting, was performed by a rheumatologist. A study nurse coordinated the physical examinations and blood testing, and managed the patient-reported questionnaires. When the last enrolled patient had been followed for 12 months the study was closed. The number of participants is low, because the study was a subproject under the multicenter study "Ultrasonographic differences in total synovitis between seropositive and seronegative rheumatoid arthritis patients", and the Fatigue Severity Scale was not included in all subprojects.

Treatment
---------

The patients in this study commenced their first biologic therapy (certolizumab, etanercept, golimumab, infliximab or rituximab) according to standard procedures and doses.

Thirty-eight patients were on stable doses of methotrexate 3 months before baseline and until visit T1. Six patients were taking leflunomide or hydroxychloroquine, and four patients had no synthetic disease-modifying antirheumatic drugs (DMARDs).

A total of 28 patients were on a stable low dose of corticosteroids the last month before inclusion and until visit T1. Patients were told to avoid analgesics for 24 h prior to the visits if possible.

Assessments
-----------

Fatigue was measured using the FSS, which is a 9-item questionnaire rated on a scale from 1 to 7, where 1 indicates strongly disagree and 7 indicates strongly agree. The FSS contains statements on the severity of fatigue, and also the effect on a person's activities and lifestyle. The developers of the FSS have suggested a cut-off of 4 for severe fatigue ([@ref-31]). The FSS is used in a number of diseases and is a reliable instrument for measuring fatigue ([@ref-46]). The FSS has demonstrated good psychometric properties and is one of the few measures that are able to detect change over time ([@ref-50]). There are different Norwegian versions of the Fatigue Severity Scale questionnaire. In this study we used a questionnaire translated in 1995. As far as we know, this version of the questionnaire has not been tested for psychometric properties. Nevertheless, it has been used in research and clinical practice for several years ([@ref-29]; [@ref-5]; [@ref-10]).

Rheumatoid Arthritis Impact of Disease (RAID) was used to measure pain and physical and emotional wellbeing ([@ref-22]). The scale goes from 0--10. Pain is assessed from none to extreme and physical and emotional wellbeing are assessed from very good to very bad. RAID has been validated ([@ref-23]).

Disease activity can be measured by the Disease Activity Score 28 (DAS28). The purpose is to combine single measures such as swollen and tender joints, erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), and to include or exclude a general health assessment ([@ref-19]). In this study we wanted to use an objective tool for measuring disease activity. Therefore, we chose DAS28 based on three variables: tender and swollen joint counts and ESR ([@ref-18]). DAS28 has been validated to monitor disease activity in RA ([@ref-48]).

Statistical analyses
--------------------

Descriptive statistics were used to describe sociodemographic, patient-reported and health personnel-reported variables. The independent samples *t*-test was used to test for differences between women and men. The paired samples *t*-test was used to test for differences between measures at different points in time.

Linear mixed effect analyses were used to identify possible predictors of change in fatigue. In the analyses, we added clinical variables such as DAS28, sociodemographic variables such as sex and age, and patient-reported variables such as pain and physical and emotional wellbeing. First, a 0-model containing time only was made using simple contrasts in time domain, i.e., a comparison of each time point with baseline. In step 1, to estimate the main effect and interaction effect, each predictor was put into a model containing time. The Akaikes information criterion (AIC) was used as a criterion to decide whether the model fitted the data and also to compare the models to the 0-model by measuring the *p*-value and performing a likelihood ratio test. In step 2, significant predictors were put into a model one by one. RAID subscales were added in order of their AIC score. In step 3 only predictors contributing to the model were added.

We used a linear mixed effects model with simple contrasts including all time points, i.e., the model has a built-in-adjustment for baseline. The main effect of a predictor is the effect at baseline, while the interaction describes if and how the baseline effect changes over time.

The significance level was set to 0.05. SPSS 23 for Windows (IBM Corp., Armonk, NY) and R 3.3.0 ([@ref-43]) with the package nlme 3.1 ([@ref-38]) were used for the statistical analyses.

Ethical considerations
----------------------

The study was approved by the Regional Ethics committee for Medical Research (REK, 2011/490). All the patients received both oral and written information, and signed informed consent.

Results
=======

A total of 48 patients met the inclusion criteria, and gave consent to participate in the study. One patient was excluded after 3 months because of acute illness and need of surgery. 47 patients completed the study ([Fig. 1](#fig-1){ref-type="fig"}).

![Flowchart.\
Flowchart to show number of participants who completed the study.](peerj-07-6771-g001){#fig-1}

At baseline the patients had a median age of 55 years \[range 24--73 years\], and more than half of the patients (56%) were women. The mean disease duration was 5 years (SD 7.5), \[range \<1--40 years\]. Sociodemographic and clinical baseline characteristics are shown in [Table 1](#table-1){ref-type="table"}.
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###### Sociodemographic characteristics such as age, sex, civil status, children living at home, occupational activity.

Clinical characteristics such as disease duration, rheumatoid factor, anti-cyclic citrullinated peptide, erythrocyte sedimentation rate, C-reactive protein, Disease Activity Score of 28 joints, Fatigue Severity Scale, Rheumatoid Arthritis Impact of Disease.
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  ------------------------------------------------------------------------- -----------------
  **Sociodemographic characteristics**                                      *n* = 48
  Age, years, median (range)                                                55.0 \[24--73\]
  Sex, female, *n* (%)                                                      27 (56%)
  Married/living with partner, *n* (%)                                      34 (71%)
  Children living at home, *n* (%)                                          22 (46%)
  Working or studying (full-time or part-time), *n* (%)                     24 (50%)
  Working or studying patients on sick leave, *n* (%) 10 (21%)              
  Disability benefits (full-time or part-time), *n* (%)                     10 (21%)
  Retired, *n* (%)                                                          4 (8%)
  **Clinical characteristics**                                              
  Disease duration, years, mean (SD)                                        5.0 (7.5)
  RF, *n* (%)                                                               33 (69%)
  Anti-CCP, *n* (%)                                                         38 (79%)
  ESR (mm/h), median (range)                                                22.5 \[0--75\]
  CRP (mg/L), median (range)                                                9.0 \[0--58\]
  Prednisolon dosage, mean (SD)[^a^](#table-1fn2){ref-type="fn"}            6.0 (3.2)
  Methotrexate dosage, mean (SD)[^b^](#table-1fn3){ref-type="fn"}           20.0 (4.8)
  FSS, (1--7), mean (SD)[^c^](#table-1fn4){ref-type="fn"}                   4.4 (1.5)
  DAS28, mean (SD)                                                          4.5 (1.2)
  RAID - pain, mean (SD)[^d^](#table-1fn5){ref-type="fn"}                   5.5 (2.1)
  RAID - emotional well-being, mean (SD)[^e^](#table-1fn6){ref-type="fn"}   3.9 (2.1)
  RAID - physical well-being, mean (SD)[^d^](#table-1fn5){ref-type="fn"}    4.9 (1.9)
  ------------------------------------------------------------------------- -----------------

**Notes.**

RFrheumatoid factorAnti-CCPanti-cyclic citrullinated peptideESRerythrocyte sedimentation rateCRPC-reactive proteinDAS28Disease Activity Score of 28 jointsFSSFatigue Severity ScaleRAIDRheumatoid Arthritis Impact of Disease

*n* = 28.

*n* = 38.

*n* = 47.

*n* = 45.

*n* = 44.

The mean fatigue measurements and their changes are shown in [Table 2](#table-2){ref-type="table"}. At baseline we observed significantly more severe fatigue in female than in male patients. The severity of fatigue decreased significantly for both women and men between baseline and visit T1 and then stabilized. This improvement was stronger for women (mean (CI) = 1.3 (0.7,1.9), *p* \< 0.001) than for men, (mean (CI) = 0.6 (0.8,1.2), *p* = 0.026).

10.7717/peerj.6771/table-2

###### Mean, 95% confidence intervals and *p*-values of changes in fatigue during the study, and test of differences between women and men.
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                       Women   Men             FSS difference                                                                                                                             
  ---------------- --- ------- --------------- ---------------- ------------------------------------------ ---- --------------- ---------------- ---------------------------------------- -----------------------------------------
  Baseline (T0)    1   26      5.0 (4.5,5.5)   --               --                                         21   3.6 (2.9,4.3)   --               --                                       0.001[^\*^](#table-2fn3){ref-type="fn"}
  3 months (T1)    0   27      3.7 (3.1,4.4)   1.3 (0.7,1.9)    \<0.001[^†^](#table-2fn2){ref-type="fn"}   21   3.0 (2.3,3.6)   0.6 (0.8,1.2)    0,026[^†^](#table-2fn2){ref-type="fn"}   0.113[^\*^](#table-2fn3){ref-type="fn"}
  6 months (T2)    0   27      3.4 (2.7,4.1)   1.6 (0.9,2.3)    \<0.001[^†^](#table-2fn2){ref-type="fn"}   20   3.0 (2.3,3.7)   0.6 (−0.3,1.5)   0,155[^†^](#table-2fn2){ref-type="fn"}   0.368[^\*^](#table-2fn3){ref-type="fn"}
  12 months (T3)   2   25      3.7 (2.9,4.4)   1.4 (0.7,2.0)    \<0.001[^†^](#table-2fn2){ref-type="fn"}   20   2.7 (1.9,3.5)   0.9 (0.1,1.6)    0,024[^†^](#table-2fn2){ref-type="fn"}   0.078[^\*^](#table-2fn3){ref-type="fn"}

**Notes.**

FSSFatigue severity scale, scale 0--7: lower scores represent less fatigueCIConfidence interval

paired *t*-test.

*t*-test.

As shown in [Table 3](#table-3){ref-type="table"} the disease activity measured by DAS28 decreased significantly between baseline and 3 months (mean (CI) = 1.4 (1.1,1.7), *p* \< 0.001) and was stable in later visits. The same development was observed for the selected RAID subscales. In the linear mixed effects model, sex and RAID emotional well-being contributed significantly to the model (Step 2 in [Table 4](#table-4){ref-type="table"}), while change in fatigue was not explained by disease activity (Step 1 in [Table 4](#table-4){ref-type="table"}).

10.7717/peerj.6771/table-3

###### Mean changes, 95% confidence intervals and *p*-values during the one-year observation study of fatigue, including both women and men.
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  Measure                                                      *T*1: change from *T*0                                              *T*2: change from *T*0                                              *T*3: change from *T*0   
  ------------------------------------------------------------ ------------------------ ------------------------------------------ ------------------------ ------------------------------------------ ------------------------ ------------------------------------------
                                                               Mean (95% CI)            *p*                                        Mean (95% CI)            *p*                                        Mean (95 CI)             *p*
  DAS28                                                        1.4 (1.1,1.7)            \<0.001[^†^](#table-3fn4){ref-type="fn"}   1.4 (1.1,1.8)            \<0.001[^†^](#table-3fn4){ref-type="fn"}   1.6 (1.3,1.9)            \<0.001[^†^](#table-3fn4){ref-type="fn"}
  RAID pain[^a^](#table-3fn2){ref-type="fn"}                   2.4 (1.6,3.3)            \<0.001[^†^](#table-3fn4){ref-type="fn"}   2.2 (2.8,0.4)            \<0.001[^†^](#table-3fn4){ref-type="fn"}   3.2 (2.3,4.0)            \<0.001[^†^](#table-3fn4){ref-type="fn"}
  RAID physical well-being[^b^](#table-3fn3){ref-type="fn"}    1.8 (1.1,2.5)            \<0.001[^†^](#table-3fn4){ref-type="fn"}   2.0 (1.2,2.7)            \<0.001[^†^](#table-3fn4){ref-type="fn"}   2.3 (1.5,3.1)            \<0.001[^†^](#table-3fn4){ref-type="fn"}
  RAID emotional well-being[^b^](#table-3fn3){ref-type="fn"}   1.4 (0.7,2.1)            \<0.001[^†^](#table-3fn4){ref-type="fn"}   1.7 (1.0,2.4)            \<0.001[^†^](#table-3fn4){ref-type="fn"}   1.3 (0.3,2.2)            0.012[^†^](#table-3fn4){ref-type="fn"}

**Notes.**

T0before the intervention*T*1after three months*T*2after six months*T*3after twelve monthsDAS28Disease activity score 28RAIDRheumatoid Arthritis Impact of DiseaseCIConfidence interval

Scale 0--10, lower scores represent less pain.

Scale 0--10, lower scores represent more well-being.

paired *t*-test.

10.7717/peerj.6771/table-4

###### Predictors of fatigue: mean changes, 95% confidence intervals and *p*-values, including both women and men.
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                                                    **Step 1**[^a^](#table-4fn1){ref-type="fn"}   **Step 2**[^b^](#table-4fn2){ref-type="fn"}   **Final model**[^c^](#table-4fn3){ref-type="fn"}                                         
  ------------ ------------------------------------ --------------------------------------------- --------------------------------------------- -------------------------------------------------- ---------- -------------------------- ----------
  DAS28        Main effect                          0.06 (−0.26, 0.38)                            ,706                                          --                                                 --         --                         --
               Effect change: BL -\>3 months        0.34 (−0.09, 0.76)                            ,126                                          --                                                 --         --                         --
               Effect change: BL -\>6 months        0.13 (−0.32, 0.59)                            ,569                                          --                                                 --         --                         --
               Effect change: BL -\>12 months       −0.02 (−0.46, 0.43)                           ,937                                          --                                                 --         --                         --
  Age          Main effect                          −0.04 (−0.08, 0)                              ,081                                          --                                                 --         --                         --
               Effect change: BL -\>3 months        0 (−0.04, 0.04)                               ,856                                          --                                                 --         --                         --
               Effect change: BL -\>6 months        0.03 (−0.02, 0.07)                            ,234                                          --                                                 --         --                         --
               Effect change: BL -\>12 months       0.02 (−0.03, 0.06)                            ,450                                          --                                                 --         --                         --
  Sex          **Main effect**                      **1.49 (0.54, 2.43)**                         **,003**                                      **1.27 (0.34, 2.2)**                               **,013**   **1.29 (0.36, 2.23)**      **,010**
               Effect change: BL -\>3 months        −0.56 (−1.45, 0.34)                           ,235                                          0.09 (−0.17, 0.34)                                 ,524       0.12 (−0.08, 0.32)         ,255
               Effect change: BL -\>6 months        −1.13 (−2.05, −0.21)                          ,019                                          0.03 (−0.16, 0.22)                                 ,802       −0.57 (−1.46, 0.32)        ,220
               **Effect change: BL -\>12 months**   **-0.58 (−1.52, 0.36)**                       **,236**                                      **0.04 (−0.16, 0.25)**                             **,687**   **-1.19 (−2.11, −0.27)**   **,015**
  RAID         Main effect                          0.2 (0.01, 0.39)                              ,047                                          −0.69 (−1.56, 0.18)                                ,144       −0.38 (−1.31, 0.55)        ,440
  physical     Effect change: BL -\>3 months        0.13 (−0.13, 0.38)                            ,336                                          −1.15 (−2.03, −0.28)                               ,016       0.19 (−0.06, 0.45)         ,155
  well-being   Effect change: BL -\>6 months        0.04 (−0.21, 0.28)                            ,773                                          −0.38 (−1.27, 0.5)                                 ,423       0.14 (−0.11, 0.4)          ,284
               Effect change: BL -\>12 months       −0.06 (−0.32, 0.2)                            ,649                                          0.15 (−0.19, 0.49)                                 ,418       0.02 (−0.25, 0.28)         ,912
  RAID         Main effect                          0.14 (−0.03, 0.31)                            ,113                                          −0.15 (−0.54, 0.23)                                ,464       --                         --
  emotional    Effect change: BL -\>3 months        0.16 (−0.08, 0.39)                            ,199                                          −0.12 (−0.52, 0.27)                                ,561       --                         --
  well-being   Effect change: BL -\>6 months        0.31 (0.07, 0.56)                             ,016                                          0.09 (−0.21, 0.39)                                 ,591       **--**                     **--**
               Effect change: BL -\>12 months       0.02 (−0.2, 0.23)                             ,882                                          0.39 (0.09, 0.68)                                  ,015       --                         --
  RAID         Main effect                          0.1 (−0.08, 0.29)                             ,283                                          0.04 (−0.26, 0.35)                                 ,782       --                         --
  pain         Effect change: BL -\>3 months        0.08 (−0.17, 0.32)                            ,540                                          0.01 (−0.25, 0.28)                                 ,919       --                         --
               Effect change: BL -\>6 months        0.14 (−0.1, 0.38)                             ,257                                          0.11 (−0.23, 0.45)                                 ,541       --                         --
               Effect change: BL -\>12 months       0.08 (−0.19, 0.35)                            ,552                                          0.14 (−0.18, 0.46)                                 ,422       --                         --

**Notes.**

Model with one predictor (main effect and interaction).

Model including sex, RAID physical well-being, RAID emotional well-being, RAID pain.

Model including sex, RAID physical well-being.

BLbaselineCIconfidence intervalDAS28Disease Activity Score of 28 jointsRAIDRheumatoid Arthritis Impact of Disease

Analysis of predictors ([Table 4](#table-4){ref-type="table"}) showed a higher reduction in fatigue values at follow-up visit T2 (6 months) for women than men (*p* = 0.019). At follow-up visit T3 (12 months) there was a significant change in fatigue for females (*p* = 0.015). The changes in fatigue and the RAID variables pain and physical and emotional wellbeing are explained by the gender component. The change in fatigue is explained by both female sex and physical wellbeing, but in the end female sex had stronger influence than physical wellbeing and turned out to be a significant predictor for change in fatigue (*p* = 0.010).

Discussion
==========

Changes in patient-reported fatigue
-----------------------------------

This study found that both female and male RA patients commencing biologic therapy reported lower levels of fatigue during treatment. Previous research has shown somewhat inconsistent results and, to our knowledge, has not examined gender differences. In a randomized clinical trial, [@ref-36] reported no significant effect of biologics on fatigue in Sjögren's patients. However, a post hoc analysis showed that six out of 12 patients in the group treated with biologics reported a 50% reduction in fatigue compared to one out of 13 in the placebo group, and this result was significant. Another study investigated the effect of biologics on work ability, functional disability and fatigue. The results from this observational study showed significant improvements in fatigue after six months of biologic therapy ([@ref-27]). These inconsistencies may be explained by the fact that fatigue is a patient-reported symptom with individual variations in severity and etiology and by the different diseases studied. In some patients, fatigue may persist despite biologic therapy ([@ref-16]) and the explanation for this may be found in the etiology of fatigue as a symptom with multiple causes, some connected to disease activity and others to personal factors ([@ref-24]). When RA patients with fatigue were interviewed and encouraged to describe this problem in their own words, they described fatigue as an experience that was always present, preventing them from finding solutions to everyday problems and affecting both themselves and their social life ([@ref-6]). A broader approach covering all aspects of this health problem is needed.

Possible predictors for changes in fatigue
------------------------------------------

In bivariate analyses, disease activity and age turned out to be insignificant predictors for change in fatigue at all follow-up visits. Pain also turned out to be an insignificant predictor for change in fatigue in both bivariate and multivariate analyses. Emotional wellbeing turned out to be a significant predictor for change in fatigue at the 6-month follow-up visit in bivariate analyses and at the 12-month follow-up visit in multivariate analyses. In bivariate analyses physical well-being was a statistically significant predictor of change in fatigue, but in multivariate analyses only the 3-month follow-up visit showed a significant change in fatigue. Female sex was a significant predictor in both bivariate and multivariate analyses. As far as we know, in previous research sex has rarely been a variable in analyses of predictors of change in fatigue, and the results of this study may be difficult to compare to other studies. However, it might be possible to compare the results of the patient and health personnel-reported outcomes in this study. In a systematic review, [@ref-33] found that disease activity was positively related to fatigue when pain was not considered, and that pain was the dominating factor related to fatigue. However, in these studies disease activity was measured using different components of DAS28, and the various components of DAS28 have different weightings, with some of them being more related to inflammation than others. It might therefore be difficult to compare the results of these studies ([@ref-33]). In this study, women reported statistically significantly higher fatigue at baseline than men. During the study the mean fatigue score was higher in women at all follow-up visits. Previous work has shown that women report higher values of fatigue than men ([@ref-40]; [@ref-44]), and several factors, such as genetic and hormonal factors and other exposures that may be experienced differently by women and men, have been suggested as explanations for the difference between men and women in terms of RA disease impact ([@ref-49]). Pain and related **measurements** are often discussed as being **non-sex-neutral**. In a review, somatic symptom reporting in women and men has been examined. Results showed that women reported more numerous, more intense and more frequent bodily symptoms than men ([@ref-7]). Moreover, women and men may react differently to treatment. In a register-based observational study of predictors of response to biologic therapy, there was a lower remission rate among female RA patients ([@ref-28]).

In this present study, multivariate analyses showed that change in fatigue is explained by both female sex and physical wellbeing. Still, in the final model only female sex turned out to be a significant predictor for change in fatigue.

Strengths and limitations of the study
--------------------------------------

The strength and importance of this study of fatigue in patients with rheumatoid arthritis is the insight and information gained on patient-reported outcomes. The data are based on the implementation of outcome measures recommended by experts ([@ref-26]), and guidelines from the European League Against Rheumatism and the American College of Rheumatology ([@ref-2]), and recommendations from the international research cooperation Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) ([@ref-11]). This study is a cohort study, without a control group. Therefore, it is difficult to determine whether biologic therapy affects fatigue or not. On the other hand, the patients in the study had tried standard treatment with synthetic DMARDs before commencing biologics. The patients' level of fatigue was followed up for twelve months, and data collection was performed four times, and this may provide valuable insight into how fatigue occurs. Furthermore, the number of participants was small, which means that the analyses have low statistical power, and they were all recruited from the same rheumatology department. However, the participants were recruited consecutively and were all in need of their first biologic treatment, and had no major co-morbidities. The patients in the study live along the west coast of Norway, but we assume the selection is not very different from the majority of RA patients living in other parts of Norway ([@ref-8]; [@ref-37]).

Conclusion
==========

Female RA patients commencing biologics report reductions in fatigue after 3 and 6 months. After 12 months there is a slight increase in the fatigue level. Male RA patients report reductions in fatigue after 3 and 12 months. When comparing sociodemographic, patient-reported and health personnel-reported variables, female sex was a significant predictor of changes in fatigue. This result is important and may indicate gender differences in the impact of RA. Further research is needed in order to understand the complexity of fatigue and to evaluate non-pharmacological treatment.

Relevance to clinical practice
------------------------------

Fatigue is a burdensome symptom in RA patients, and despite improvements in the pharmacological treatment of RA, patients still report fatigue ([@ref-47]; [@ref-13]; [@ref-33]). Therefore, additional therapies are needed to combat fatigue. These therapies should take into account that fatigue is a multifaceted health problem encompassing personal and emotional factors in addition to the clinical factors directly connected to the disease.
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